Progress, Potential, and Possibilities Podcast / Show · 2026-05-14 · 40 min
Send us Fan Mail What if the next breakthrough cancer therapy can’t be manufactured on Earth at all? In this episode, BioOrbit CEO Dr. Katie King explains how microgravity may unlock entirely new classes of medicines - from ultra-precise biologics to cancer therapies manufactured in orbit aboard future pharmaceutical factories in space. Dr. Katie King, Ph.D is a scientist, entrepreneur, and space-tech innovator working at the intersection of biotechnology, nanomedicine, and orbital manufacturing. Dr. King is the Co-Founder and CEO of BioOrbit ( ), a pioneering company developing pharmaceutical manufacturing platforms in microgravity with the goal of revolutionizing cancer treatment. BioOrbit is focused on producing next-generation medicines in space - particularly highly structured biologics and crystallized therapeutics that may be difficult or impossible to manufacture optimally on Earth due to gravity-driven limitations. The company is preparing for a major in-orbit demonstration mission connected to the International Space Station and upcoming launch activity in 2026. Dr. King earned her Ph.D.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100Inside the Global Biotech Ecosystem - Where Innovation Goes Next | Sara Jane Demy - Founder and CEO, Demy-ColtonReversing Cellular Age: The Scientist Who Helped Create iPS Cells Reveals What’s Next - Dr. Koji Tanabe, Ph.D. - Founder and CEO, I Peace Inc.The End of High Cholesterol? The First Oral PCSK9 Drug Could Change Heart Medicine Forever - Dr. Norman Lepor, MD - Founder and Director, National Heart InstituteThe Hidden Heart Risk: Amgen’s Dr. Paul Burton on the Future of Preventing Heart Attacks - Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P. - Senior Vice President and Chief Medical Officer - Amgen
